Mark K Buyyounouski, MD, MS

Publications

• Randomized Trial of Hypofractionated External-Beam Radiotherapy for Prostate Cancer
  Pollack, A., Walker, G., Horwitz, E. M., Price, R., Feigenberg, S., & Buyyounouski, M. K. (2013). Randomized Trial of Hypofractionated External-Beam Radiotherapy for Prostate Cancer. JOURNAL OF CLINICAL ONCOLOGY, 31(31), 3860-?.
• Gleason Scoring at a Comprehensive Cancer Center: What's The Difference?
  Townsend, N. C., Ruth, K., Al-Saleem, T., Horwitz, E. M., Sobczak, M., & Buyyounouski, M. K. (2013). Gleason Scoring at a Comprehensive Cancer Center: What's The Difference?. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(7), 812-819.
• Assessment of the American Joint Committee on Cancer Staging (Sixth and Seventh Editions) for Clinically Localized Prostate Cancer Treated With External Beam Radiotherapy and Comparison With the National Comprehensive Cancer Network Risk-Stratification Method
  Zaorsky, N. G., Li, T., Devarajan, K., Horwitz, E. M., & Buyyounouski, M. K. (2012). Assessment of the American Joint Committee on Cancer Staging (Sixth and Seventh Editions) for Clinically Localized Prostate Cancer Treated With External Beam Radiotherapy and Comparison With the National Comprehensive Cancer Network Risk-Stratification Method. CANCER, 118(22), 5535-5543.
• Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer Buyyounouski, M. K., Pickles, T., Kestin, L. L., Allison, R., & Williams, S. G. (2012). Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer. JOURNAL OF CLINICAL ONCOLOGY, 30(15), 1857-1863.
  
• RADIOTHERAPY DOSES OF 80 GY AND HIGHER ARE ASSOCIATED WITH LOWER MORTALITY IN MEN WITH GLEASON SCORE 8 TO 10 PROSTATE CANCER Pahlajani, N., Ruth, K. J., Buyyounouski, M. K., Chen, D. Yt., Horwitz, E. M., & Pollack, A. (2012). RADIOTHERAPY DOSES OF 80 GY AND HIGHER ARE ASSOCIATED WITH LOWER MORTALITY IN MEN WITH GLEASON SCORE 8 TO 10 PROSTATE CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 82(5), 1949-1956.
  
• DEVELOPMENT OF RTOG CONSENSUS GUIDELINES FOR THE DEFINITION OF THE CLINICAL TARGET VOLUME FOR POSTOPERATIVE CONFORMAL RADIATION THERAPY FOR PROSTATE CANCER Michalski, J. M., Lawton, C., El Naqa, I., Ritter, M., O'Meara, E., & Menard, C. (2010). DEVELOPMENT OF RTOG CONSENSUS GUIDELINES FOR THE DEFINITION OF THE CLINICAL TARGET VOLUME FOR POSTOPERATIVE CONFORMAL RADIATION THERAPY FOR PROSTATE CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 76(2), 361-368.
  
• Comparison of testicular dose delivered by intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) in patients with prostate cancer Martin, J. M., Handorf, E. A., Price, R. A., Cherian, G., Buyyounouski, M. K., & Horwitz, E. M. (2015). Comparison of testicular dose delivered by intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) in patients with prostate cancer. MEDICAL DOSIMETRY, 40(3), 186-189.
  
• Development and preliminary testing of PROGRESS: a Web-based education program for prostate cancer survivors transitioning from active treatment Miller, S. M., Hudson, S. V., Hui, S.- kuen A., Diefenbach, M. A., Fleisher, L., & Baman, J. (2015). Development and preliminary testing of PROGRESS: a Web-based education program for prostate cancer survivors transitioning from active treatment. JOURNAL OF CANCER SURVIVORSHIP, 9(3), 541-553.
  
• Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with modern treatment techniques. Murphy, C. T., Heller, S., Ruth, K., Buyyounouski, M. K., Weinberg, D., & Horwitz, E. M. (2015). Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with modern treatment techniques. Practical radiation oncology, 5(3), e215-22.
  
• Post-radiotherapy prostate biopsies reveal heightened apex positivity relative to other prostate regions sampled Huang, K. T., Stoyanova, R., Walker, G., Sandler, K., Studenski, M. T., & Pollack, A. (2015). Post-radiotherapy prostate biopsies reveal heightened apex positivity relative to other prostate regions sampled. RADIOTHERAPY AND ONCOLOGY, 115(1), 101-106.
  
• Salvage low-dose-rate I-125 partial prostate brachytherapy after dose-escalated external beam radiotherapy Chang, L., & Buyyounouski, M. K. (2014). Salvage low-dose-rate I-125 partial prostate brachytherapy after dose-escalated external beam radiotherapy. JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 6(3), 304-310.
  
• Reply to m.j. Brenner et Al and I.R. Vogelius et Al. Pollack, A., Walker, G., Horwitz, E. M., Price, R., Feigenberg, S., & Buyyounouski, M. K. (2014). Reply to m.j. Brenner et Al and I.R. Vogelius et Al. Journal of clinical oncology , 32(17), 1853-1854.
  
• Tadalafil for Prevention of Erectile Dysfunction After Radiotherapy for Prostate Cancer The Radiation Therapy Oncology Group [0831] Randomized Clinical Trial Pisansky, T. M., Pugh, S. L., Greenberg, R. E., Pervez, N., Reed, D. R., & Bruner, D. W. (2014). Tadalafil for Prevention of Erectile Dysfunction After Radiotherapy for Prostate Cancer The Radiation Therapy Oncology Group [0831] Randomized Clinical Trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 311(13), 1300-1307.
  
• Does family history of prostate cancer affect outcomes following radiotherapy? Bagshaw, H., Ruth, K., Horwitz, E. M., Chen, D. Yt., & Buyyounouski, M. K. (2014). Does family history of prostate cancer affect outcomes following radiotherapy?. RADIOTHERAPY AND ONCOLOGY, 110(2), 229-234.
  
• Inflammatory Bowel Disease Is Not an Absolute Contraindication to Definitive Radiation Therapy for Prostate Cancer Murphy, C., Ruth, K. J., Buyyounouski, M. K., Heller, S., Weinberg, D., & Horwitz, E. M. (2013). Inflammatory Bowel Disease Is Not an Absolute Contraindication to Definitive Radiation Therapy for Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87(2), S356-S356.
  
• CT-MRI Fusion Uncertainty in Prostate Treatment Planning for Different Image Guidance Techniques Chen, X., Xue, J., Chen, L., Buyyounouski, M. K., Horwitz, E. M., & Ma, C. (2013). CT-MRI Fusion Uncertainty in Prostate Treatment Planning for Different Image Guidance Techniques. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87(2), S718-S718.
  
• Toxicity and Biochemical Failure Following Image-Guided Prostate Intensity Modulated Radiation Therapy: Fiducial Markers Versus Electromagnetic Transponders Chang, L., Li, T., Horwitz, E., Chen, D. Yt., Viterbo, R., & Buyyounouski, M. K. (2013). Toxicity and Biochemical Failure Following Image-Guided Prostate Intensity Modulated Radiation Therapy: Fiducial Markers Versus Electromagnetic Transponders. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87(2), S368-S369.
  
• Improved Outcomes in Men Treated With Adjuvant or Early Salvage Postprostatectomy IMRT or 3DCRT at a Single Institution Murphy, C., Uzzo, R. G., Ruth, K. J., Viterbo, R., Plimack, E., & Greenberg, R. E. (2013). Improved Outcomes in Men Treated With Adjuvant or Early Salvage Postprostatectomy IMRT or 3DCRT at a Single Institution. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87(2), S378-S378.
  
• Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial Mitin, T., Hunt, D., Shipley, W. U., Kaufman, D. S., Uzzo, R., & Zietman, A. L. (2013). Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. LANCET ONCOLOGY, 14(9), 863-872.
  
• Stratifying intermediate-risk patients for radiotherapy Buyyounouski, M. K. (2013). Stratifying intermediate-risk patients for radiotherapy. NATURE REVIEWS UROLOGY, 10(8), 438-439.
  
• Reduction of prostate intrafractional motion from shortening the treatment time Li, J. S., Lin, M.-H., Buyyounouski, M. K., Horwitz, E. M., & Ma, C.-M. (2013). Reduction of prostate intrafractional motion from shortening the treatment time. PHYSICS IN MEDICINE AND BIOLOGY, 58(14), 4921-4932.
  
• A Novel Method for Predicting Late Genitourinary Toxicity After Prostate Radiation Therapy and the Need for Age-Based Risk-Adapted Dose Constraints Ahmed, A. A., Egleston, B., Alcantara, P., Li, L., Pollack, A., & Buyyounouski, M. K. (2013). A Novel Method for Predicting Late Genitourinary Toxicity After Prostate Radiation Therapy and the Need for Age-Based Risk-Adapted Dose Constraints. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 86(4), 709-715.
  
• Untitled Reply Turaka, A., Buyyounouski, M. K., Horwitz, E. M., & Movsas, B. (2013). Untitled Reply. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 86(1), 6-7.
  
• In reply to Cheung. Turaka, A., Buyyounouski, M. K., Horwitz, E. M., & Movsas, B. (2013). In reply to Cheung. International journal of radiation oncology, biology, physics, 86(1), 6-7.
  
• Seminal Vesicle Target Delineation for Intermediate-Risk Prostate Cancer IMRT. Johnson, M. E., Ruth, K., Buyyounouski, M. K., & Horwitz, E. M. (2013). Seminal Vesicle Target Delineation for Intermediate-Risk Prostate Cancer IMRT. Practical radiation oncology, 3(2), S31-2.
  
• The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms Stoyanova, R., Pahlajani, N. H., Egleston, B. L., Buyyounouski, M. K., Chen, D. Yt., & Pollack, A. (2013). The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms. CANCER, 119(5), 1080-1088.
  
• Prospective Validation of Diagnostic Tumor Tissue Ki-67 as the Most Significant Predictor of Outcome in Men Treated for Prostate Cancer on a Randomized Trial Pollack, A., Walker, G., Stoyanova, R., Khor, L., Horwitz, E., & Buyyounouski, M. (2012). Prospective Validation of Diagnostic Tumor Tissue Ki-67 as the Most Significant Predictor of Outcome in Men Treated for Prostate Cancer on a Randomized Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S25-S26.
  
• Primary Prostate Radiation Therapy: Where Are We Failing? Huang, K. T., Walker, G., Stoyanova, R., SANDLER, K., Horwitz, E., & Pollack, A. (2012). Primary Prostate Radiation Therapy: Where Are We Failing?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S182-S182.
  
• Determinants of Prostate Biopsy Positivity 2 Years After Radiation Therapy for Men With Prostate Cancer Treated on a Randomized Trial Stoyanova, R., Walker, G., SANDLER, K., Khor, L., Horwitz, E., & Pollack, A. (2012). Determinants of Prostate Biopsy Positivity 2 Years After Radiation Therapy for Men With Prostate Cancer Treated on a Randomized Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S60-S60.
  
• Do Testosterone Kinetics After Radiation Therapy (RT) Predict Biochemical Failure (BCF) for Low- and Intermediate-risk Prostate Cancer (CaP)? Martin, J. M., Sopka, D. M., Ruth, K. J., Buyyounouski, M. K., Kutikov, A., & Horwitz, E. M. (2012). Do Testosterone Kinetics After Radiation Therapy (RT) Predict Biochemical Failure (BCF) for Low- and Intermediate-risk Prostate Cancer (CaP)?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S185-S186.
  
• Recursive Partitioning Analysis of Intermediate Risk Prostate Cancer Patients Identifies Subgroup Risk Categories Townsend, N. C., Ruth, K., Buyyounouski, M., Kutikov, A., Viterbo, R., & Horwitz, E. M. (2012). Recursive Partitioning Analysis of Intermediate Risk Prostate Cancer Patients Identifies Subgroup Risk Categories. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S183-S183.
  
• A Novel Methodology to Predict Late Urinary Toxicity Following Prostate Radiation Therapy-based on Bladder Wall Dosimetry Ahmed, A., Egleston, B., Alcantara, P., Pollack, A., Li, L., & Buyyounouski, M. K. (2012). A Novel Methodology to Predict Late Urinary Toxicity Following Prostate Radiation Therapy-based on Bladder Wall Dosimetry. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S418-S419.
  
• Aspirin and Statin Nonuse Associated With Early Biochemical Failure After Prostate Radiation Therapy Zaorsky, N. G., Buyyounouski, M. K., Li, T., & Horwitz, E. M. (2012). Aspirin and Statin Nonuse Associated With Early Biochemical Failure After Prostate Radiation Therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(1), E13-E17.
  
• Prostate Bed Motion During Intensity-Modulated Radiotherapy Treatment Klayton, T., Price, R., Buyyounouski, M. K., Sobczak, M., Greenberg, R., & Horwitz, E. M. (2012). Prostate Bed Motion During Intensity-Modulated Radiotherapy Treatment. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(1), 130-136.
  
• Stamp Test Delivers Message on Erectile Dysfunction After High-dose Intensity-modulated Radiotherapy for Prostate Cancer Keller, L. Mm., Buyyounouski, M. K., Sopka, D., Ruth, K., Klayton, T., & Horwitz, E. M. (2012). Stamp Test Delivers Message on Erectile Dysfunction After High-dose Intensity-modulated Radiotherapy for Prostate Cancer. UROLOGY, 80(2), 337-342.
  
• Radiotherapy Treatment Planning for Testicular Seminoma Wilder, R. B., Buyyounouski, M. K., Efstathiou, J. A., & Beard, C. J. (2012). Radiotherapy Treatment Planning for Testicular Seminoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 83(4), E445-E452.
  
• A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 update Buyyounouski, M. K., Davis, B. J., Prestidge, B. R., Shanahan, T. G., Stock, R. G., & Horwitz, E. M. (2012). A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 update. BRACHYTHERAPY, 11(4), 299-305.
  
• Magnetic Resonance Spectroscopy of the Prostate: A Phantom Study of Metabolite Concentrations Hossain, M., Richardson, T., Buyyounouski, M. K., Schirmer, T., Noeske, R., & Ma, C. (2012). Magnetic Resonance Spectroscopy of the Prostate: A Phantom Study of Metabolite Concentrations. MEDICAL PHYSICS, 39(6), 3639-3640.
  
• How Certain Can the Real-Time Plan Predict the Post Dosimetry for Prostate Seed Implant? Li, J. S., Buyyounouski, M., Horwitz, E., & Ma, C.-M. (2012). How Certain Can the Real-Time Plan Predict the Post Dosimetry for Prostate Seed Implant?. MEDICAL PHYSICS, 39(6), 3933-3933.
  
• Effect of Gold Marker Seeds on Magnetic Resonance Spectroscopy of the Prostate Hossain, M., Schirmer, T., Richardson, T., Chen, L., Buyyounouski, M. K., & Ma, C. M. (2012). Effect of Gold Marker Seeds on Magnetic Resonance Spectroscopy of the Prostate. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 83(1), 451-458.
  
• Biochemical and clinical experience with real-time intraoperatively planned permanent prostate brachytherapy Lubbe, W., Cohen, R., Sharma, N., Ruth, K., Peters, R., & Horwitz, E. (2012). Biochemical and clinical experience with real-time intraoperatively planned permanent prostate brachytherapy. BRACHYTHERAPY, 11(3), 209-213.
  
• Testicular Cancer Clinical Practice Guidelines in Oncology Motzer, R. J., Agarwal, N., Beard, C., Bhayani, S., Bolger, G. B., & Wilder, R. B. (2012). Testicular Cancer Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(4), 502-535.
  
• Continuous localization technologies for radiotherapy delivery: Report of the American Society for Radiation Oncology Emerging Technology Committee. D'Ambrosio, D. J., Bayouth, J., Chetty, I. J., Buyyounouski, M. K., Price, R. A., & Konski, A. (2012). Continuous localization technologies for radiotherapy delivery: Report of the American Society for Radiation Oncology Emerging Technology Committee. Practical radiation oncology, 2(2), 145-150.
  
• An evidence based review of proton beam therapy: The report of ASTRO's emerging technology committee Allen, A. M., Pawlicki, T., Dong, L., Fourkal, E., Buyyounouski, M., & Konski, A. A. (2012). An evidence based review of proton beam therapy: The report of ASTRO's emerging technology committee. RADIOTHERAPY AND ONCOLOGY, 103(1), 8-11.
  
• Hypoxic Prostate/Muscle PO2 Ratio Predicts for Outcome in Patients With Localized Prostate Cancer: Long-Term Results Turaka, A., Buyyounouski, M. K., Hanlon, A. L., Horwitz, E. M., Greenberg, R. E., & Movsas, B. (2012). Hypoxic Prostate/Muscle PO2 Ratio Predicts for Outcome in Patients With Localized Prostate Cancer: Long-Term Results. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 82(3), E433-E439.
  
• Young age under 60 years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate cancer Klayton, T. L., Ruth, K., Horwitz, E. M., Uzzo, R. G., Kutikov, A., & Buyyounouski, M. K. (2011). Young age under 60 years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate cancer. RADIOTHERAPY AND ONCOLOGY, 101(3), 508-512.
  
• Long-Term Survival After Radical Prostatectomy Versus External-Beam Radiotherapy for Patients With High-Risk Prostate Cancer Boorjian, S. A., Karnes, R. J., Viterbo, R., Rangel, L. J., Bergstralh, E. J., & Buyyounouski, M. K. (2011). Long-Term Survival After Radical Prostatectomy Versus External-Beam Radiotherapy for Patients With High-Risk Prostate Cancer. CANCER, 117(13), 2883-2891.
  
• INTENSITY-MODULATED RADIOTHERAPY REDUCES GASTROINTESTINAL TOXICITY IN PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER Sharma, N. K., Li, T., Chen, D. Y., Pollack, A., Horwitz, E. M., & Buyyounouski, M. K. (2011). INTENSITY-MODULATED RADIOTHERAPY REDUCES GASTROINTESTINAL TOXICITY IN PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 80(2), 437-444.
  
• PREDICTORS OF ANDROGEN DEPRIVATION THERAPY EFFICACY COMBINED WITH PROSTATIC IRRADIATION: THE CENTRAL ROLE OF TUMOR STAGE AND RADIATION DOSE Williams, S., Buyyounouski, M., Kestin, L., Duchesne, G., & Pickles, T. (2011). PREDICTORS OF ANDROGEN DEPRIVATION THERAPY EFFICACY COMBINED WITH PROSTATIC IRRADIATION: THE CENTRAL ROLE OF TUMOR STAGE AND RADIATION DOSE. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 79(3), 724-731.
  
• The Impact of Gleason Scoring at a Comprehensive Cancer Center on the Ability to Predict Recurrence After Radiotherapy for Prostate Cancer Townsend, N. C., Ruth, K., Al-Saleem, T., Horwitz, E. M., Sobczak, M., & Buyyounouski, M. K. (2011). The Impact of Gleason Scoring at a Comprehensive Cancer Center on the Ability to Predict Recurrence After Radiotherapy for Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S409-S410.
  
• A Nomogram Predicting 5-year Probability of Cause Specific Survival from Biochemical Failure following Radiotherapy Buyyounouski, M. K., Kestin, L., Duchesne, G., Pickles, T., Allison, R., & Williams, S. (2011). A Nomogram Predicting 5-year Probability of Cause Specific Survival from Biochemical Failure following Radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S389-S389.
  
• Aspirin Use Reduces the Risk of Biochemical Failure and Distant Metastases Following Post-Prostatectomy Radiotherapy Cohen, R. J., Li, T., Horwitz, E. M., Peter, R., Uzzo, R. G., & Buyyounouski, M. K. (2011). Aspirin Use Reduces the Risk of Biochemical Failure and Distant Metastases Following Post-Prostatectomy Radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S391-S392.
  
• A Family History of Prostate Cancer is not Associated with Poorer Outcomes following Radiotherapy Bagshaw, H. P., Ruth, K., Horwitz, E. M., Chen, D., & Buyyounouski, M. K. (2011). A Family History of Prostate Cancer is not Associated with Poorer Outcomes following Radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S211-S211.
  
• VMAT Reduces Moderate to High Integral Dose When Compared to Conventional IMRT for Treatment of Prostate Cancer Lubbe, W. J., Price, R., Ruth, K., Cherian, G., Kutikov, A., & Horwitz, E. (2011). VMAT Reduces Moderate to High Integral Dose When Compared to Conventional IMRT for Treatment of Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S446-S446.
  
• Identification of a Single Nucleotide Polymorphism Related to Late Toxicity in a Randomized Hypofractionation Trial for Prostate Cancer Oh, J., Deasy, J., Stoyanova, R., Saleh, Z., Buyyounouski, M., & Pollack, A. (2011). Identification of a Single Nucleotide Polymorphism Related to Late Toxicity in a Randomized Hypofractionation Trial for Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S156-S157.
  
• Potential Treatment Margin Reduction for Prostate Treatment with RapidArc and VMAT Li, J., Buyyounouski, M. K., Lin, M., Horwitz, E. M., & Ma, C. (2011). Potential Treatment Margin Reduction for Prostate Treatment with RapidArc and VMAT. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S391-S391.
  
• Five Year Results of a Randomized External Beam Radiotherapy Hypofractionation Trial for Prostate Cancer Pollack, A., Walker, G., Buyyounouski, M., Horwitz, E., Price, R., & Ma, C. (2011). Five Year Results of a Randomized External Beam Radiotherapy Hypofractionation Trial for Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S1-S1.
  
• Genetic Polymorphisms of DNA Repair and Inflammatory Responses as Determinants of Late Toxicity in Prostate Cancer Patients Who Received Radiotherapy in a Randomized Trial Hu, J. J., Stoyanova, R., Deasy, J. O., Chung, R., Martin, E., & Pollack, A. (2011). Genetic Polymorphisms of DNA Repair and Inflammatory Responses as Determinants of Late Toxicity in Prostate Cancer Patients Who Received Radiotherapy in a Randomized Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S109-S110.
  
• Prostate Bed Motion during Intensity Modulated Radiotherapy Treatment Klayton, T. L., Price, R., Buyyounouski, M. K., Sobczak, M., Greenberg, R. E., & Horwitz, E. M. (2011). Prostate Bed Motion during Intensity Modulated Radiotherapy Treatment. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S101-S101.
  
• Treatment-related Side Effects And Quality Of Life Among Prostate Cancer Patients Treated With Conventional versus Hypofractionated Intensity Mediated Radiotherapy: A Phase III Hypofractionation Trial Jean-Pierre, P., Stoyanova, R., Penedo, F., Antoni, M., Abramowitz, M., & Pollack, A. (2011). Treatment-related Side Effects And Quality Of Life Among Prostate Cancer Patients Treated With Conventional versus Hypofractionated Intensity Mediated Radiotherapy: A Phase III Hypofractionation Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S667-S667.
  
• Implantation of electromagnetic transponders following radical prostatectomy for delivery of IMRT Canter, D., Greenberg, R. E., Horwitz, E. M., Kutikov, A., Li, J., & Boorjian, S. A. (2010). Implantation of electromagnetic transponders following radical prostatectomy for delivery of IMRT. CANADIAN JOURNAL OF UROLOGY, 17(5), 5365-5369.
  
• STEREOTACTIC BODY RADIOTHERAPY FOR EARLY-STAGE NON-SMALL-CELL LUNG CANCER: REPORT OF THE ASTRO EMERGING TECHNOLOGY COMMITTEE Buyyounouski, M. K., Balter, P., Lewis, B., D'Ambrosio, D. J., Dilling, T. J., & Wallner, P. E. (2010). STEREOTACTIC BODY RADIOTHERAPY FOR EARLY-STAGE NON-SMALL-CELL LUNG CANCER: REPORT OF THE ASTRO EMERGING TECHNOLOGY COMMITTEE. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(1), 3-10.
  
• Androgen Deprivation Therapy in High-Risk Prostate Cancer Buyyounouski, M. K. (2010). Androgen Deprivation Therapy in High-Risk Prostate Cancer. ONCOLOGY-NEW YORK, 24(9), 806-809.
  
• RADIOTHERAPY PSA nadir predicts long-term mortality Buyyounouski, M. K. (2010). RADIOTHERAPY PSA nadir predicts long-term mortality. NATURE REVIEWS CLINICAL ONCOLOGY, 7(4), 188-190.
  
• STEREOTACTIC BODY RADIOTHERAPY FOR PRIMARY MANAGEMENT OF EARLY-STAGE, LOW- TO INTERMEDIATE-RISK PROSTATE CANCER: REPORT OF THE AMERICAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY EMERGING TECHNOLOGY COMMITTEE Buyyounouski, M. K., Price, R. A., Harris, E. Er., Miller, R., Tome, W., & Wallner, P. E. (2010). STEREOTACTIC BODY RADIOTHERAPY FOR PRIMARY MANAGEMENT OF EARLY-STAGE, LOW- TO INTERMEDIATE-RISK PROSTATE CANCER: REPORT OF THE AMERICAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY EMERGING TECHNOLOGY COMMITTEE. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 76(5), 1297-1304.
  
• An intraoperative real-time sleeved seed technique for permanent prostate brachytherapy Sharma, N. K., Cohen, R. J., Eade, T. N., Buyyounouski, M. K., Uzzo, R. G., & Horwitz, E. M. (2010). An intraoperative real-time sleeved seed technique for permanent prostate brachytherapy. BRACHYTHERAPY, 9(2), 126-130.
  
• Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population Kaplan, D. J., Boorjian, S. A., Ruth, K., Egleston, B. L., Chen, D. Yt., & Giri, V. N. (2010). Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population. BJU INTERNATIONAL, 105(3), 334-337.
  
• Young Age under 60 is not a Contraindication to Treatment with Definitive High Dose External Beam Radiation Therapy Prostate Cancer Klayton, T. L., Ruth, K., Horwitz, E. M., Uzzo, R. G., Kuritzky, N. K., & Buyyounouski, M. K. (2010). Young Age under 60 is not a Contraindication to Treatment with Definitive High Dose External Beam Radiation Therapy Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S334-S334.
  
• Intermediate-risk Prostate Cancer Treated with High Dose Radiotherapy Alone or in Combination with Androgen Deprivation Therapy: The Fox Chase Experience Sopka, D. M., Li, T., Horwitz, E. M., Chen, D. Yt., & Buyyounouski, M. K. (2010). Intermediate-risk Prostate Cancer Treated with High Dose Radiotherapy Alone or in Combination with Androgen Deprivation Therapy: The Fox Chase Experience. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S351-S352.
  
• Low Pretreatment PET SUV Predicts for Increased Local Failure following Stereotactic Body Radiation Therapy for Lung Cancer Husain, Z. A., Sharma, N. K., Hanlon, A. L., Buyyounouski, M. K., Mirmiran, A., & Feigenberg, S. J. (2010). Low Pretreatment PET SUV Predicts for Increased Local Failure following Stereotactic Body Radiation Therapy for Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S525-S525.
  
• The Stamp Test Delivers the Message on Erectile Dysfunction following High Dose IMRT Keller, L. M., Ruth, K., Horwitz, E. M., Pollack, A., Watkins-Bruner, D., & Buyyounouski, M. K. (2010). The Stamp Test Delivers the Message on Erectile Dysfunction following High Dose IMRT. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S596-S597.
  
• Preliminary Results of RTOG 0233: A Phase II Randomized Trial for Muscle-invading Bladder Cancer Treated by Transurethral Resection and Radiotherapy Comparing Two Forms of Concurrent Induction Chemotherapy Zietman, A. L., HUNT, D., Kaufman, D. S., Uzzo, R., Wu, C., & Shipley, W. U. (2010). Preliminary Results of RTOG 0233: A Phase II Randomized Trial for Muscle-invading Bladder Cancer Treated by Transurethral Resection and Radiotherapy Comparing Two Forms of Concurrent Induction Chemotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S31-S32.
  
• A Practical Strategy to Correct Prostate Rotation Reported by a 4D Localization System Li, J., Jin, L., Horwitz, E. M., Buyyounouski, M. K., Price, R. A., & Ma, C. (2010). A Practical Strategy to Correct Prostate Rotation Reported by a 4D Localization System. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S701-S702.
  
• Interval to Biochemical Failure is Highly Prognostic for Distant Metastases and Mortality after Salvage Radiation Therapy Buyyounouski, M. K., Li, T., Turaka, A., Chen, D. Yt., & Horwitz, E. M. (2010). Interval to Biochemical Failure is Highly Prognostic for Distant Metastases and Mortality after Salvage Radiation Therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S348-S348.
  
• Conventional versus Hypofractionated IMRT: Results of Late GI and GU Toxicity and Quality of Life from a Phase III Trial Turaka, A., Zhu, F., Buyyounouski, M. K., Horwitz, E. M., Watkins-Bruner, D., & Pollack, A. (2010). Conventional versus Hypofractionated IMRT: Results of Late GI and GU Toxicity and Quality of Life from a Phase III Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S67-S67.
  
• The Role of Adjuvant and Salvage Post-Prostatectomy IMRT or 3DCRT: The Fox Chase Experience Horwitz, E. M., Sharma, N. K., Ruth, K., Silverman, J. S., Buyyounouski, M. K., & Uzzo, R. G. (2010). The Role of Adjuvant and Salvage Post-Prostatectomy IMRT or 3DCRT: The Fox Chase Experience. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S333-S334.
  
• GAINS FROM REAL-TIME TRACKING OF PROSTATE MOTION DURING EXTERNAL BEAM RADIATION THERAPY Li, J. S., Jin, L., Pollack, A., Horwitz, E. M., Buyyounouski, M. K., & Ma, C.-M. (2009). GAINS FROM REAL-TIME TRACKING OF PROSTATE MOTION DURING EXTERNAL BEAM RADIATION THERAPY. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(5), 1613-1620.
  
• Androgen Deprivation Therapy and Prostate Cancer Duration Williams, S. G., Pickles, T., & Buyyounouski, M. K. (2009). Androgen Deprivation Therapy and Prostate Cancer Duration. JOURNAL OF CLINICAL ONCOLOGY, 27(34), E228-E228.
  
• Optimal PET response following stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC) is closely related to the pre-SBRT maximum standard uptake value Feigenberg, S. J., Sharma, N., Yu Jian Q, J. Q., Lally, B., Borghaei, H., & Movsas, B. (2009). Optimal PET response following stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC) is closely related to the pre-SBRT maximum standard uptake value. JOURNAL OF THORACIC ONCOLOGY, 4(9), S734-S734.
  
• Final report of a phase I Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) for lung tumors Feigenberg, S. J., Sharma, N., Yu, J. Q., Buyyounouski, M., Borghaei, H., & Movsas, B. (2009). Final report of a phase I Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) for lung tumors. JOURNAL OF THORACIC ONCOLOGY, 4(9), S943-S943.
  
• Surveillance for Stage I Seminoma: Better the Devil You Know Than the Devil You Don't? The Lawrentschuk/Fleshner Article Reviewed Buyyounouski, M. K. (2009). Surveillance for Stage I Seminoma: Better the Devil You Know Than the Devil You Don't? The Lawrentschuk/Fleshner Article Reviewed. ONCOLOGY-NEW YORK, 23(9), 762-764.
  
• RTOG GU RADIATION ONCOLOGY SPECIALISTS REACH CONSENSUS ON PELVIC LYMPH NODE VOLUMES FOR HIGH-RISK PROSTATE CANCER Lawton, C. Af., Michalski, J., El-Naqa, I., Buyyounouski, M. K., Lee, W. R., & Seider, M. (2009). RTOG GU RADIATION ONCOLOGY SPECIALISTS REACH CONSENSUS ON PELVIC LYMPH NODE VOLUMES FOR HIGH-RISK PROSTATE CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 74(2), 383-387.
  
• Dosimetric comparison of stereotactic body radiotherapy using 4D CT and multiphase CT images for treatment planning of lung cancer: Evaluation of the impact on daily dose coverage Wang, L., Hayes, S., Paskalev, K., Jin, L., Buyyounouski, M. K., & Feigenberg, S. (2009). Dosimetric comparison of stereotactic body radiotherapy using 4D CT and multiphase CT images for treatment planning of lung cancer: Evaluation of the impact on daily dose coverage. RADIOTHERAPY AND ONCOLOGY, 91(3), 314-324.
  
• Correlation of hypoxic prostate/muscle p(O2) (P/M P-O2) ratio and biochemical failure in patients with localized prostate cancer: Long-term results Turaka, A., Buyyounouski, M. K., Hanlon, A. L., Horwitz, E. M., Greenberg, R. E., & Movsas, B. (2009). Correlation of hypoxic prostate/muscle p(O2) (P/M P-O2) ratio and biochemical failure in patients with localized prostate cancer: Long-term results. JOURNAL OF CLINICAL ONCOLOGY, 27(15).
  
• Residual Prostate Cancer After Radiotherapy: A Study of Radical Cystoprostatectomy Specimens Editorial Comment Kaplan, D. J., Crispen, P. L., Greenberg, R. E., Chen, D. Y., Viterbo, R., & Uzzo, R. G. (2009). Residual Prostate Cancer After Radiotherapy: A Study of Radical Cystoprostatectomy Specimens Editorial Comment. JOURNAL OF UROLOGY, 181(5), 2111-2112.
  
• Race, Genetic West African Ancestry, and Prostate Cancer Prediction by Prostate-Specific Antigen in Prospectively Screened High-Risk Men Giri, V. N., Egleston, B., Ruth, K., Uzzo, R. G., Chen, D. Yt., & Kittles, R. (2009). Race, Genetic West African Ancestry, and Prostate Cancer Prediction by Prostate-Specific Antigen in Prospectively Screened High-Risk Men. CANCER PREVENTION RESEARCH, 2(3), 244-250.
  
• Initial PSA (iPSA) and Radiation Dose Predict for an Undetectable PSA following 3DCRT or IMRT for Low-intermediate Risk Prostate Cancer Sharma, N. K., Ruth, K. J., Boorjian, S. A., Uzzo, R. G., Buyyounouski, M. K., & Horwitz, E. M. (2009). Initial PSA (iPSA) and Radiation Dose Predict for an Undetectable PSA following 3DCRT or IMRT for Low-intermediate Risk Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S313-S313.
  
• Defining Biochemical Failure following Salvage Radiotherapy Lubbe, W. J., Ruth, K., Devarajan, K., Horwitz, E. M., Boorjian, S., & Buyyounouski, M. K. (2009). Defining Biochemical Failure following Salvage Radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S330-S330.
  
• A Potential Outcomes Framework to Determine Whether Age and Medical Co-morbidities Predict Who is Harmed by Combined Androgen Deprivation Therapy Silverman, J. S., Egleston, B., Horwitz, E. M., Chen, D. Yt., & Buyyounouski, M. K. (2009). A Potential Outcomes Framework to Determine Whether Age and Medical Co-morbidities Predict Who is Harmed by Combined Androgen Deprivation Therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S326-S326.
  
• Is MRI-based Week Three Post-implant Dosimetry Necessary following LDR Prostate Brachytherapy? Cohen, R. J., Sharma, N. K., Ruth, K., Buyyounouski, M. K., Li, J., & Horwitz, E. M. (2009). Is MRI-based Week Three Post-implant Dosimetry Necessary following LDR Prostate Brachytherapy?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S298-S298.
  
• Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer Buyyounouski, M. K., Pickles, T., Kestin, L., Allison, R., & Williams, S. G. (2009). Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S103-S104.
  
• Undetectable Post-treatment PSA following 3DCRT or IMRT Alone for Patients with Low or Intermediate Risk Prostate Cancer is an Independent Predictor of Biochemical and Clinical Outcome Horwitz, E. M., Ruth, K. J., Sharma, N. K., Chen, D. Yt., Buyyounouski, M. K., & Uzzo, R. G. (2009). Undetectable Post-treatment PSA following 3DCRT or IMRT Alone for Patients with Low or Intermediate Risk Prostate Cancer is an Independent Predictor of Biochemical and Clinical Outcome. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S301-S301.
  
• Hypofractionation for Prostate Cancer: Interim Results of a Randomized Trial Pollack, A., Li, T., Buyyounouski, M., Horwitz, E., Price, R., & Ma, C. (2009). Hypofractionation for Prostate Cancer: Interim Results of a Randomized Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S81-S82.
  
• DOES TREATMENT DURATION AFFECT OUTCOME AFTER RADIOTHERAPY FOR PROSTATE CANCER? D'Ambrosio, D. J., Li, T., Horwitz, E. M., Chen, D. Yt., Pollack, A., & Buyyounouski, M. K. (2008). DOES TREATMENT DURATION AFFECT OUTCOME AFTER RADIOTHERAPY FOR PROSTATE CANCER?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(5), 1402-1407.
  
• Residual prostate cancer after radiotherapy: A study of radical cystoprostatectomy specimens Kaplan, D. J., Crispen, P. L., Greenberg, R. E., Chen, D. Yt., Viterbo, R., & Uzzo, R. G. (2008). Residual prostate cancer after radiotherapy: A study of radical cystoprostatectomy specimens. UROLOGY, 72(3), 654-658.
  
• Comment on dose escalation and biochemical failure in prostate cancer: In regard to Kuban et al. (Int J Radiat Oncol Biol Phys 2008;70 : 67-74) - In reply to Drs. Schultz and Kagan Pollack, A., Eade, T. M., Horwitz, E. M., Buyyounouski, M. K., & Hanks, G. E. (2008). Comment on dose escalation and biochemical failure in prostate cancer: In regard to Kuban et al. (Int J Radiat Oncol Biol Phys 2008;70 : 67-74) - In reply to Drs. Schultz and Kagan. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 71(4), 1288-1289.
  
• A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or I-125 permanent implant Eade, T. N., Horwitz, E. M., Ruth, K., Buyyounouski, M. K., D'Ambrosio, D. J., & Pollack, A. (2008). A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or I-125 permanent implant. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 71(2), 338-345.
  
• Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer? D'Ambrosio, D. J., Ruth, K., Horwitz, E. M., Chen, D. Yt., Pollack, A., & Buyyounouski, M. K. (2008). Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?. UROLOGY, 71(5), 938-941.
  
• Influence of local tumor control on distant metastases and cancer related mortality after external, beam radiotherapy for prostate cancer - Editorial comment Buyyounouski, M. K. (2008). Influence of local tumor control on distant metastases and cancer related mortality after external, beam radiotherapy for prostate cancer - Editorial comment. JOURNAL OF UROLOGY, 179(4), 1373-1373.
  
• How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier? D'Ambrosio, D. J., Ruth, K., Horwitz, E. M., Uzzo, R. G., Pollack, A., & Buyyounouski, M. K. (2008). How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 70(5), 1487-1491.
  
• Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: Statistical significance without predictive performance Williams, S. G., Buyyounouski, M. K., Pickles, T., Kestin, L., Martinez, A., & Duchesne, G. M. (2008). Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: Statistical significance without predictive performance. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 70(4), 1169-1175.
  
• Commentary on dose escalation and biochemical failure in prostate cancer: In regard to Eade et al. (Int J Radiat Oncol Biol Phys 2007;68 : 682-689) - In reply Pollack, A., Eade, T. N., Hanlon, A. L., Horwitz, E. M., Buyyounouski, M. K., & Hanks, G. E. (2008). Commentary on dose escalation and biochemical failure in prostate cancer: In regard to Eade et al. (Int J Radiat Oncol Biol Phys 2007;68 : 682-689) - In reply. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 70(2), 645-646.
  
• Predicting local persistence of intermediate and high-risk prostate cancer using percentage of adenocarcinoma in pretreatment biopsy tissue Buyyounouski, M. K., Li, T., Al-Saleem, T., Horwitz, E., Konski, A., & Pollack, A. (2008). Predicting local persistence of intermediate and high-risk prostate cancer using percentage of adenocarcinoma in pretreatment biopsy tissue. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S321-S322.
  
• Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy Buyyounouski, M. K., Hanlon, A. L., Horwitz, E. M., & Pollack, A. (2008). Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 70(1), 59-66.
  
• Low morbidity and excellent local control using image guided stereotactic body radiotherapy (IGSBRT) for lung tumors Sharma, N. K., Ruth, K., Konski, A. A., Buyyounouski, M. K., Nicolaou, N., & Feigenberg, S. J. (2008). Low morbidity and excellent local control using image guided stereotactic body radiotherapy (IGSBRT) for lung tumors. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S454-S454.
  
• Gains from real-time prostate motion monitoring during external beam radiation therapy Li, J., Jin, L., Horwitz, E., Buyyounouski, M., Pollack, A., & Ma, C. (2008). Gains from real-time prostate motion monitoring during external beam radiation therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S287-S288.
  
• The optimum duration of combination androgen deprivation therapy (ADT) with prostate cancer radiotherapy: Determining the duration-benefit relationship from multi-institutional analysis Pickles, T., Williams, S. G., Buyyounouski, M. K., Kestin, L. L., & Duchesne, G. M. (2008). The optimum duration of combination androgen deprivation therapy (ADT) with prostate cancer radiotherapy: Determining the duration-benefit relationship from multi-institutional analysis. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S73-S73.
  
• The phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer Abramowitz, M. C., Li, T., Buyyounouski, M. K., Ross, E., Uzzo, R. G., & Horwitz, E. M. (2008). The phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. CANCER, 112(1), 55-60.
  
• Androgen deprivation therapy plus hypofractionated prostate radiotherapy-are we castrating the radiobiological advantage? Williams, S. G., Pickles, T., Kestin, L., Buyyounouski, M., Martinez, A., & Duchesne, G. (2008). Androgen deprivation therapy plus hypofractionated prostate radiotherapy-are we castrating the radiobiological advantage?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S73-S74.
  
• Radiation therapy for high risk prostate cancer: Do patients 70 years or older benefit from combined androgen deprivation therapy? Silverman, J. S., Ruth, K., Horwitz, E. M., Pollack, A., Chen, D. Yt., & Buyyounouski, M. K. (2008). Radiation therapy for high risk prostate cancer: Do patients 70 years or older benefit from combined androgen deprivation therapy?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S75-S76.
  
• Estimating gains in biochemical outcome from various durations of androgen deprivation in patients treated with dose escalated radiotherapy for prostate cancer using two nomograms Pahlajani, N. H., Egleston, B. L., Buyyounouski, M. K., Chen, D. Yt., Horwitz, E., & Pollack, A. (2008). Estimating gains in biochemical outcome from various durations of androgen deprivation in patients treated with dose escalated radiotherapy for prostate cancer using two nomograms. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S54-S54.
  
• PSA doubling time predicts for the development of distant metastases for patients who fail 3DCRT or IMRT using the Phoenix definition Horwitz, E. M., Ruth, K., Uzzo, R. G., Buyyounouski, M. K., Wong, Y., & Pollack, A. (2008). PSA doubling time predicts for the development of distant metastases for patients who fail 3DCRT or IMRT using the Phoenix definition. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S135-S136.
  
• Prostate cancer risk assessment program: A 10-year update of cancer detection Giri, V. N., Beebe-Dimmer, J., Buyyounouski, M., Konski, A., Feigenberg, S. J., & Watkins-Bruner, D. (2007). Prostate cancer risk assessment program: A 10-year update of cancer detection. JOURNAL OF UROLOGY, 178(5), 1920-1924.
  
• Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy Morgan, P. B., Hanlon, A. L., Horwitz, E. M., Buyyounouski, M. K., Uzzo, R. G., & Pollack, A. (2007). Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. CANCER, 110(1), 68-80.
  
• What dose of external-beam radiation is high enough for prostate cancer? Eade, T. N., Hanlon, A. L., Horwitz, E. M., Buyyounouski, M. K., Hanks, G. E., & Pollack, A. (2007). What dose of external-beam radiation is high enough for prostate cancer?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 68(3), 682-689.
  
• Daily localization for prostate bed patients based on surgical clips Paskalev, K., Horwitz, E., Price, R., Feigenberg, S., Buyyounouski, M., & Pollack, A. (2007). Daily localization for prostate bed patients based on surgical clips. MEDICAL PHYSICS, 34(6), 2381-2382.
  
• Dosimetric comparison of 4D and 3 multi-phase CT imaging for stereotactic body radiation therapy (SBRT) planning in lung cancer Wang, L., Jin, L., Hayes, S., Paskalev, K., Buyyounouski, M., & Feigenberg, S. (2007). Dosimetric comparison of 4D and 3 multi-phase CT imaging for stereotactic body radiation therapy (SBRT) planning in lung cancer. MEDICAL PHYSICS, 34(6), 2384-2384.
  
• Surface smoothing of a tubular structure using a non-shrinking algorithm Chen, Y., Paskalev, K., Horwitz, E., Price, R., Buyyounouski, M., & Pollack, A. (2007). Surface smoothing of a tubular structure using a non-shrinking algorithm. MEDICAL PHYSICS, 34(6), 2637-2637.
  
• Do stranded seeds improve the quality of permanent prostate seed implant? Li, J., Horwitz, E., Buyyounouski, M., McNeeley, S., Crawford, K., & Ma, C. (2007). Do stranded seeds improve the quality of permanent prostate seed implant?. MEDICAL PHYSICS, 34(6), 2330-2330.
  
• Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate Eade, T. N., Al-Saleem, T., Horwitz, E. M., Buyyounouski, M. K., Chen, D. Yt., & Pollack, A. (2007). Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate. CANCER, 109(10), 2011-2015.
  
• Radiation dose and late failures in prostate cancer Morgan, P. B., Hanlon, A. L., Horwitz, E. M., Buyyounouski, M. K., Uzzo, R. G., & Pollack, A. (2007). Radiation dose and late failures in prostate cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 67(4), 1074-1081.
  
• The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer D'Ambrosio, D. J., Hanlon, A. L., Al-Saleem, T., Feigenberg, S. J., Horwitz, E. M., & Buyyounouski, M. K. (2007). The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 67(4), 1082-1087.
  
• FDG PET response by 3 months following stereotactic body radiotherapy for non-small cell lung cancer may be an early surrogate of local failure Feigenberg, S., Yu, J. Qm., Eade, T. N., Buyyounouski, M., Wang, L., & Movsas, B. (2007). FDG PET response by 3 months following stereotactic body radiotherapy for non-small cell lung cancer may be an early surrogate of local failure. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3), S479-S480.
  
• Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death Alcantara, P., Hanlon, A., Buyyounouski, M. K., Horwitz, E. M., & Pollack, A. (2007). Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. CANCER, 109(1), 41-47.
  
• A matched pair comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy for prostate cancer: Toxicity and outcomes Morgan, P. B., Ruth, K., Horwitz, E. M., Buyyounouski, M. K., Uzzo, R. G., & Pollack, A. (2007). A matched pair comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy for prostate cancer: Toxicity and outcomes. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3), S319-S319.
  
• Intensity modulated radiation therapy reduces gastrointestinal morbidity in patients treated with androgen deprivation therapy for prostate cancer Sharma, N. K., Li, T., Horwitz, E. M., Pollack, A., & Buyyounouski, M. K. (2007). Intensity modulated radiation therapy reduces gastrointestinal morbidity in patients treated with androgen deprivation therapy for prostate cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3), S10-S10.
  
• Does total treatment duration affect outcome in prostate cancer treated with radiotherapy? D'Ambrosio, D. J., Horwitz, T. Lem., Chen, D., Pollack, A., & Buyyounouski, M. K. (2007). Does total treatment duration affect outcome in prostate cancer treated with radiotherapy?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3), S176-S176.
  
• A comparison of sexual function following radiotherapy for prostate cancer: Results of a prospective, randomized trial of hypofractionated intensity modulated radiotherapy Buyyounouski, M. K., Li, T., Watkins-Bruner, D., Horwitz, E. M., & Pollack, A. (2007). A comparison of sexual function following radiotherapy for prostate cancer: Results of a prospective, randomized trial of hypofractionated intensity modulated radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3), S7-S8.
  
• Effect of target smoothness on treatment planning for prostate IMRT Chen, Y., Paskalev, K., Horwitz, E., Price, R., Buyyounouski, M., & Pollack, A. (2007). Effect of target smoothness on treatment planning for prostate IMRT. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3), S649-S649.
  
• Impact of pelvic nodal irradiation with intensity-modulated radiotherapy on treatment of prostate cancer Price, R. A., Hannoun-Levi, J.-M., Horvvitz, E., Buyyounouski, M., Ruth, K. J., & Pollack, A. (2006). Impact of pelvic nodal irradiation with intensity-modulated radiotherapy on treatment of prostate cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(2), 583-592.
  
• Daily changes in seminal vesicle location during treatment of prostate carcinoma McNeeley, S., Paskalev, K., Buyyounouski, M., & Ma, C. (2006). Daily changes in seminal vesicle location during treatment of prostate carcinoma. MEDICAL PHYSICS, 33(6), 2030-2030.
  
• Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial Pollack, A., Hanlon, A. L., Horwitz, E. M., Feigenberg, S. J., Konski, A. A., & Price, R. A. (2006). Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 64(2), 518-526.
  
• CT-based daily localization of prostate patients: Anatomy vs. implanted markers Paskalev, K., Feigenberg, S., McNeeley, S., Horwitz, E., Price, R., & Alan, P. (2006). CT-based daily localization of prostate patients: Anatomy vs. implanted markers. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S621-S621.
  
• Increasing radiotherapy dose for prostate cancer reduces a late wave of distant metastasis Morgan, P. B., Hanlon, A. L., Horwitz, E. M., Buyyounouski, M. K., Uzzo, R. G., & Pollack, A. (2006). Increasing radiotherapy dose for prostate cancer reduces a late wave of distant metastasis. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S9-S10.
  
• The prostate specific antigen velocity is unaltered by radiotherapy alone when 2 ng/mL per year or greater: Distant metastasis are the cause Buyyounouski, M. K., Hanlon, A. L., Horwitz, E. M., & Pollack, A. (2006). The prostate specific antigen velocity is unaltered by radiotherapy alone when 2 ng/mL per year or greater: Distant metastasis are the cause. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S206-S207.
  
• Intensity modulated radiation therapy for prostate cancer: Preliminary results on treatment morbidity compared to 3-D conformal radiation therapy Kirichenko, A. V., Ruth, K., Horwitz, E. M., Buyyounouski, M. K., Feigenberg, S. J., & Pollack, A. (2006). Intensity modulated radiation therapy for prostate cancer: Preliminary results on treatment morbidity compared to 3-D conformal radiation therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S326-S326.
  
• Comparison of outcomes in low risk prostate cancer: I-125 seed brachytherapy vs. intensity modulated radiotherapy Eade, T. N., Ruth, K., D'Ambrosio, D. J., Feigenberg, S. J., Buyyounouski, M. K., & Horwitz, E. M. (2006). Comparison of outcomes in low risk prostate cancer: I-125 seed brachytherapy vs. intensity modulated radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S60-S61.
  
• Smoking and its relationship to GU and GI toxicity in prostate cancer patients treated with radiation Pahlajani, N. H., Ruth, K., Horwitz, E. M., Buyyounouski, M. B., Chen, D. Y., & Pollack, A. (2006). Smoking and its relationship to GU and GI toxicity in prostate cancer patients treated with radiation. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S317-S317.
  
• Adjusted radiotherapy dose response curves following treatment for prostate cancer: Biochemical failure and distant metastasis Hanlon, A. L., Horwitz, E. M., Buyyounouski, M. K., & Pollack, A. (2006). Adjusted radiotherapy dose response curves following treatment for prostate cancer: Biochemical failure and distant metastasis. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S346-S347.
  
• Prostate specific antigen kinetics in men treated with radiotherapy and androgen deprivation D'Ambrosio, D. J., Ruth, K., Buyyounouski, M. K., Horwitz, E. M., Uzzo, R. G., & Pollack, A. (2006). Prostate specific antigen kinetics in men treated with radiotherapy and androgen deprivation. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S334-S334.
  
• The nadir+2 definition of biochemical failure predicts for overall survival Abramowitz, M. C., Li, T., Ross, E., Buyyounouski, M., Uzzo, R. G., & Horwitz, E. M. (2006). The nadir+2 definition of biochemical failure predicts for overall survival. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S207-S208.
  
• Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer Buyyounouski, M. K., Hanlon, A. L., Eisenberg, D. F., Horwitz, E. M., Feigenberg, S. J., & Pollack, A. (2005). Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 63(5), 1455-1462.
  
• Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation Buyyounouski, M. K., Hanlon, A. L., Horwitz, E. M., Uzzo, R. G., & Pollack, A. (2005). Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 61(5), 1291-1298.
  
• In regard to Selek et al. erectile dysfunction and radiation dose to penile base structures: a lack of correlation. IJROBP 2004;59:1039-1046. Buyyounouski, M. K., Hanlon, A. L., Price, R. A., Horwitz, E. M., Feigenberg, S. J., & Pollack, A. (2004). In regard to Selek et al. erectile dysfunction and radiation dose to penile base structures: a lack of correlation. IJROBP 2004;59:1039-1046. International journal of radiation oncology, biology, physics, 60(5), 1664-1665.
  
• The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy Buyyounouski, M. K., Horwitz, E. M., Uzzo, R. G., Price, R. A., McNeeley, S. W., & Pollack, A. (2004). The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 59(5), 1383-1391.
  
• Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment Buyyounouski, M. K., Horwitz, E. M., Price, R. A., Hanlon, A. L., Uzzo, R. G., & Pollack, A. (2004). Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 58(3), 743-749.
  
• Re: improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the search database. Buyyounouski, M. K., Horwitz, E. M., Hanlon, A. L., Uzzo, R. G., & Pollack, A. (2004). Re: improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the search database. journal of urology, 171(3), 1246-1247.
  
• Positive prostate biopsy laterality and implications for staging Buyyounouski, M. K., Horwitz, E. M., Hanlon, A. L., Uzzo, R. G., Hanks, G. E., & Pollack, A. (2003). Positive prostate biopsy laterality and implications for staging. UROLOGY, 62(2), 298-303.
  
• Prostate cancer gene therapy and the role of radiation Kaminski, J. M., Nguyen, K., Buyyounouski, M., & Pollack, A. (2002). Prostate cancer gene therapy and the role of radiation. CANCER TREATMENT REVIEWS, 28(1), 49-64.